Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viemed HealthcareVMD +1.43%93 9-Day RSI is 64.51 as of Jul. 17, 2026. GuruFocus rates VMD with a GF Score™ of 93/100 and a GF Value™ of $10.94 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 869 Medical Devices & Instruments companies, Viemed Healthcare ranks worse than 75.95% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Viemed Healthcare's 9-Day RSI or its related term are showing as below:
VMD's 9-Day RSI is ranked worse than 75.95% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 49.23
vs VMD: 64.51
Viemed Healthcare (NAS:VMD) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Viemed Healthcare 9-Day RSI Related Terms
VMD vs DCTH, VREX, SI: 9-Day RSI Comparison
For the Medical Devices subindustry, Viemed Healthcare's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viemed Healthcare 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Viemed Healthcare's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viemed Healthcare (VMD) has a 9-Day RSI of 64.51 as of Jul. 17, 2026. According to the industry distribution chart, Viemed Healthcare ranks #660 out of 869 companies in the Medical Devices & Instruments industry, placing it in the top 75.9%.
Is Viemed Healthcare's 9-Day RSI too high?
Viemed Healthcare's current 9-Day RSI is 64.51. The Medical Devices & Instruments industry median 9-Day RSI is 49.23. Viemed Healthcare's value of 64.51 is 31% above this industry median. Based on the distribution chart, Viemed Healthcare ranks #660 out of 869 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Viemed Healthcare has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viemed Healthcare's 9-Day RSI compare to DCTH and VREX?
According to the Medical Devices & Instruments industry distribution chart, Viemed Healthcare ranks #660 out of 869 companies for 9-Day RSI. This places Viemed Healthcare in the lower half of its industry. The industry median 9-Day RSI is 49.23. Viemed Healthcare's value of 64.51 is 31% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 49.23, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viemed Healthcare's current 9-Day RSI of 64.51 is 31% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 49.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viemed Healthcare's current 9-Day RSI is 64.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viemed Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Viemed Healthcare (VMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.94, compared to a current price of $12.11 — trading 10.7% above its estimated fair value. The current 9-Day RSI is 64.51 and 31% above the Medical Devices & Instruments industry median of 49.23. Viemed Healthcare's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Viemed Healthcare (VMD), the current 9-Day RSI is 64.51 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viemed Healthcare (VMD) Overvalued in 2026?
Based on GuruFocus' analysis, Viemed Healthcare stock appears to be overvalued.
The current stock price of $12.11 is trading 10.7% above its estimated GF Value™ of $10.94.
GuruFocus considers Viemed Healthcare to be Modestly Overvalued.
Key valuation signals for VMD:
9-Day RSI: 64.51
GF Value™: $10.94 vs. price of $12.11 (10.7% above fair value)
Industry Position: 31% above the Medical Devices & Instruments median (#660 of 869)
No single metric tells the full story. See the VMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
93GF Score
Get the complete analysis for VMD
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMD has been successfully added to your 
